ICMR Funds Pan-India Clinical Trial to Test Cost-Effective Dosing of PARP Inhibitor in Ovarian Cancer

The trial, titled Intermittent PARP Inhibitor Regimen in Ovarian Cancer (IPIROC), will evaluate whether an intermittent, twice-weekly dosing strategy of the PARP inhibitor rucaparib can reduce side effects and costs while maintaining clinical efficacy in ovarian cancer patients.